NBI-31772 (5-100 μg; icv; immediately or at 1, 2, or, 3 hours after MCAO) at the time of ischemia onset also dose-dependently reduced infarct size, and the highest dose (100 μg) significantly reduced both total and cortical infarct volume.
Animal Model: |
Sprague-Dawley rats (subtemporal middle cerebral artery occlusion model, MCAO) |
Dosage: |
5-100 μg |
Administration: |
Icv; immediately or at 1, 2, or, 3 hours after MCAO |
Result: |
Resulted in a significant reduction of the total and cortical lesion volume.
|